Get the Stockscreener App
3.74
1.58%
-0.06
Pre-market:
3.79
0.05
+1.34%
Macrogenics Inc stock is traded at $3.74, with a volume of 604.61K.
It is down -1.58% in the last 24 hours and down -10.31% over the past month.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
See More
Previous Close:
$3.80
Open:
$3.79
24h Volume:
604.61K
Relative Volume:
0.78
Market Cap:
$238.24M
Revenue:
$157.08M
Net Income/Loss:
$-70.36M
P/E Ratio:
-3.3645
EPS:
-1.1116
Net Cash Flow:
$-71.69M
1W Performance:
-9.66%
1M Performance:
-10.31%
6M Performance:
+17.98%
1Y Performance:
+126.67%
1-Day Range:
$3.72
$3.86
1-Week Range:
$3.62
$4.20
52-Week Range:
$1.29
$5.08
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
3.74 | 238.24M | 157.08M | -70.36M | -71.69M | -1.1116 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Upgrade | B. Riley Securities | Neutral → Buy |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
Form 144 MACROGENICS INC. For: 27 September By Investing.com - Investing.com Australia
MacroGenics, Inc. (MGNX) Stock Price History & Data - Traders Union
MacroGenics stock falls 3.95 percent as pipeline expands - AD HOC NEWS
MacroGenics stock holds at USD 4.12 as cash strength stands out - AD HOC NEWS
Former MacroGenics (NASDAQ: MGNX) officer lines up another stock sale - Stock Titan
MacroGenics stock edges lower as biotech analysts highlight risk and upside - AD HOC NEWS
MacroGenics, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (MGNX) - Traders Union
MacroGenics2026 Funding Rounds & List of Investors - Tracxn
MacroGenics (NASDAQ:MGNX): A Minervini Trend Template High-Growth Momentum Case Study - ChartMill
MGNX: Transformed structure, strong cash, and advancing antibody pipeline with key clinical milestones ahead - TradingView
MacroGenics at H.C. Wainwright conference: leaner model, rich pipeline - Investing.com
MGNX Stock Hits 16-Month High, But This Analyst Sees Another 140% Potential Upside - Stocktwits
MacroGenics CEO Eric Risser to present at H.C. Wainwright Global Investment Conference - Bitget
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead (NASDAQ:MGNX) - Seeking Alpha
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Macrogenics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
MacroGenics (MGNX) Edges Higher as Biotech Momentum Builds, Holds Key SupportWave Alternation - dars.gov.et
Macrogenics Inc (MGNX) Senior VP, GC, and Secretary Jeffrey Pete - GuruFocus
Macrogenics senior VP sells $129,085 in shares By Investing.com - Investing.com Australia
Macrogenics senior VP sells $129,085 in shares - Investing.com
MacroGenics (MGNX) counsel sells 31K shares, now holds none - Stock Titan
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
MacroGenics (NASDAQ: MGNX) officer prepares stock sales under Rule 144 - Stock Titan
MacroGenics (MGNX) Insider Trading Activity 2026 - MarketBeat
MacroGenics (MGNX) Q1 2026 Results: The Bottom-Line Figure Beats Its Comparison in the Latest Session - vinanet.vn
MacroGenics (MGNX) exec adds 40K shares via option exercise - Stock Titan
MacroGenics (NASDAQ: MGNX) insider lines up new stock sale after recent trade - Stock Titan
MGNX Maintained by B. Riley Securities -- Price Target Raised to $11.00 - GuruFocus
B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating - marketscreener.com
MacroGenics (MGNX) Stock Faces A Revenue Reality Check After Deeper Losses - Sahm
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? - Yahoo Finance
MacroGenics 2026: Revenue $32.83M, EPS $0.31— 10-Q Summary - TradingView
MacroGenics (MGNX) gains $86M on CDMO sale as royalties and milestones rise - Stock Titan
Armistice Capital (MGNX) discloses 5.0M-share MacroGenics position in 13G/A - Stock Titan
MacroGenics Inc earnings missed by $1.02, revenue fell short of estimates - Investing.com Nigeria
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position - The Manila Times
MacroGenics (NASDAQ:MGNX) Posts Earnings Results, Beats Estimates By $0.39 EPS - MarketBeat
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
MacroGenics sells GMP ops to Bora for $122.5 million - scanx.trade
MacroGenics Q2 adj. EPS $(0.27) misses $(0.13) estimate; sales miss - scanx.trade
MacroGenics: Q2 Earnings Snapshot - AOL.com
MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner - marketscreener.com
Gilead exercises option for MacroGenics pre-clinical bispecific program - The Pharma Letter
MacroGenics, Inc. $MGNX Shares Bought by Wasatch Advisors LP - MarketBeat
MacroGenics、2026年第2四半期の財務結果を発表、運営モデルのスリム化と財務基盤の強化を実現 - Moomoo
MGNX Q1 2026 Earnings: Narrow EPS Surprise Slightly Offsets Stock DeclineEarnings Surprise Report - Vinanet
Gilead exercises option on MacroGenics bispecific program By Investing.com - Investing.com UK
MacroGenics stock rises on $10M Gilead option exercise By Investing.com - Investing.com India
MacroGenics stock rises on $10M Gilead option exercise - Investing.com
Gilead exercises option on MacroGenics bispecific program - Investing.com
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program - The Manila Times
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):